About
Hybrigenics is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases. Hybrigenics’ development program is based on inecalcitol, a vitamin D receptor agonist...
Hybrigenics is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases. Hybrigenics’ development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Inecalcitol has been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. Two clinical Phase II studies of inecalcitol are currently ongoing in chronic myeloid leukemia and acute myeloid leukemia. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics’ research program is exploring the role of enzymes called Ubiquitin-Specific Proteases (USP) in the balance between degradation and recycling of proteins called onco-proteins due to their involvement in various cancers. Hybrigenics is evaluating the interest of inhibitors of USP as anti-cancer drug candidates. Hybrigenics has collaborated with Servier on one particular USP in oncology. In this R&D program, two milestones have been reached and additional milestones may be achieved until registration of a potential drug.
  • 26
    Oct
    17
    News Release
    Hybrigenics half-year 2017 results
  • 9
    Oct
    17
    News Release
    Hybrigenics’ compound inhibits Ubiqitin-Specific Protease 10 (USP10) and shows activity in preclinical models of Acute Myeloid Leukemia (AML)
  • 24
    Jul
    17
    Corporate Update
    Hybrigenics raises € 6.8 million
  • 14
    Jun
    17
    Equity Research
    Hybrigenics SA (EPA:ALHYG) Research Update
  • 6
    Jun
    17
    News Release
    Hybrigenics gets European patent protection for inhibitors of Ubiquitin-Specific Protease 8 (USP8)
  • 18
    May
    17
    News Release
    Hybrigenics’ inhibitor of Ubiquitin-Specific Protease 7 (USP7) shows activity in preclinical models of Chronic Lymphocytic Leukemia (CLL)
  • 28
    Apr
    17
    News Release
    Hybrigenics full year 2016 results
  • 3
    Apr
    17
    News Release
    Hybrigenics presents new results on the specificity of inecalcitol in acute myeloid leukemia and multiple myeloma at AACR 2017
  • 13
    Mar
    17
    News Release
    Hybrigenics: strategic refocusing on biopharmaceutical R&D - Increase by 30% to €6.1m in total constant scope turnover
  • 14
    Feb
    17
    Company Presentation
    Hybrigenics Bio-CEO & Investor Presentation
  • 9
    Feb
    17
    News Release
    Hybrigenics: Encouraging preliminary results of the Phase II clinical study of inecalcitol in Chronic Myeloid Leukemia
  • 6
    Feb
    17
    Equity Research
    Hybrigenics SA (EPA:ALHYG) Research Update
  • 26
    Jan
    17
    News Release
    Hybrigenics’ patent estate of inhibitors of ubiquitin-specific proteases continues to expand
  • 5
    Dec
    16
    News Release
    Hybrigenics presented expanded in vitro results on inecalcitol in multiple myeloma and acute myeloid leukemia
  • 28
    Nov
    16
    News Release
    Hybrigenics enrolls a first patient in the United States in the clinical study of inecalcitol in acute myeloid leukemia patients unfit for chemotherapy
  • 3
    Nov
    16
    News Release
    Hybrigenics will present new in vitro results on inecalcitol in multiple myeloma and acute myeloid leukemia at the annual ASH meeting in San Diego, USA
  • 25
    Oct
    16
    News Release
    Hybrigenics half-year 2016 financial results and pharmaceutical R&D highlights
  • 10
    Oct
    16
    News Release
    Hybrigenics and Servier reach a new step in their R&D partnership
  • 13
    Sep
    16
    News Release
    Hybrigenics enrolls a first patient in France in the clinical study of inecalcitol in acute myeloid leukemia
  • 7
    Sep
    16
    News Release
    The collaboration between Hybrigenics and the MD Anderson Cancer Center is nominated for the final round of the MedStartUp Awards 2016
  • 28
    Jun
    16
    News Release
    Hybrigenics’ 2016 Annual General Meeting highlights and outcome: all resolutions approved
  • 2
    Jun
    16
    Equity Research
    Hybrigenics SA (EPA:ALHYG) Research Update
  • 25
    Apr
    16
    News Release
    Hybrigenics full year 2015 results
  • 4
    Apr
    16
    News Release
    Hybrigenics’ inecalcitol strengthens key patent protection in the United States until 2031
  • 27
    Jan
    16
    Company Presentation
    Hybrigenics BioMed Event Presentation - 27 janvier 2016
  • 14
    Jan
    16
    Company Presentation
    Hybrigenics Investor Presentation Update
  • 11
    Jan
    16
    News Release
    Hybrigenics receives FDA green light for Phase II clinical study of inecalcitol in Acute Myeloid Leukemia in the United States
  • 14
    Dec
    15
    News Release
    Hybrigenics receives green light for a double-blind placebo-controlled Phase II clinical study of inecalcitol in Acute Myeloid Leukemia (AML)
  • 19
    Nov
    15
    News Release
    Hybrigenics will present new in vitro results on inecalcitol in chronic myeloid leukemia (CML) at the ASH meeting in Orlando, USA
  • 16
    Nov
    15
    News Release
    Hybrigenics set up an international Clinical Advisory Board
  • 19
    Oct
    15
    News Release
    Hybrigenics 2015 first-half results and highlights
  • 8
    Oct
    15
    Equity Research
    Hybrigenics (EPA:ALHYG) Research Update
  • 10
    Aug
    15
    News Release
    Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Acute Myeloid Leukemia in the United States
  • 27
    Jul
    15
    News Release
    Hybrigenics first half 2015 revenues and cash
  • 1
    Jul
    15
    News Release
    New appointments within Hybrigenics’ Board of Directors
  • 25
    Jun
    15
    News Release
    Hybrigenics’ Annual General Meeting: all resolutions approved
  • 22
    Jun
    15
    News Release
    Hybrigenics' inecalcitol receives positive opinion from EMA for orphan drug designation in acute myeloid leukemia
  • 10
    Jun
    15
    News Release
    Hybrigenics: convening of another Shareholders’ Meeting on June 25, 2015
  • 3
    Jun
    15
    Equity Research
    Hybrigenics (EPA:ALHYG) Research Update
  • 29
    May
    15
    News Release
    Hybrigenics presents new in vitro results on inecalcitol in breast cancer at the ASCO meeting in Chicago, USA
  • 28
    Apr
    15
    News Release
    A joint project between PicoSeq, Hybrigenics, École Normale Supérieure and CNRS is selected for the second phase of the French Worldwide Innovation Challenge
  • 27
    Apr
    15
    News Release
    Hybrigenics full year 2014 results
  • 20
    Apr
    15
    News Release
    Hybrigenics presents new in vitro results on inecalcitol in chronic myeloid leukemia at the AACR meeting in Philadelphia, USA
  • 6
    Mar
    15
    Equity Research
    Hybrigenics (EPA:ALHYG) Research Update
  • 2
    Feb
    15
    News Release
    Hybrigenics 2014 revenues and cash
  • 26
    Jan
    15
    News Release
    Hybrigenics extends its partnership with Servier in the field of Ubiquitin-Specific Proteases inhibitors
  • 19
    Jan
    15
    News Release
    Hybrigenics launches Phase II clinical study of inecalcitol in chronic myeloid leukemia
  • 28
    Oct
    14
    News Release
    ALHYG 2014 first-half results and highlights
  • 22
    Oct
    14
    News Release
    ALHYG successfully raised €4.6 million
  • 1
    Oct
    14
    News Release
    ALHYG invests in its genomic capabilities
  • 4
    Sep
    14
    News Release
    Hybrigenics’ patent estate of inhibitors of ubiquitin-specific proteases is expanding
  • 23
    Jul
    14
    News Release
    First half 2014 revenues and cash
  • 16
    Jul
    14
    News Release
    Hybrigenics gives an update on the clinical development of inecalcitol
  • 23
    Jun
    14
    News Release
    Hybrigenics’ Inecalcitol increases the efficiency of azacitidine on acute myeloid leukemia in preclinical models
  • 23
    Jun
    14
    Equity Research
    ALHYG Equity Research Update
  • 6
    Jun
    14
    News Release
    Minutes of the annual general meeting
  • 20
    May
    14
    News Release
    Inécalcitol receives the orphan drug FDA designation for the treatement of chronic lymphocytic leukemia in the United States
  • 19
    May
    14
    News Release
    Hybrigenics Services reçoit le prix du nouveau service le plus innovant de l'année lors de la 4ème conférence européenne sur l'automatisation des laboratoires
  • 3
    Apr
    14
    News Release
    Hybrigenics lance Helixio, sa nouvelle gamme de services génomiques
  • 1
    Apr
    14
    News Release
    rejoint l’indice CAC® PME d’Euronext
  • 31
    Mar
    14
    News Release
    résultats annuels 2013 en forte progression
  • 26
    Mar
    14
    News Release
    réalise une levée de fonds de 6,1 millions d’euros
  • 5
    Mar
    14
    News Release
    Hybrigenics' inecalcitol shows potential in acute myeloid leukemia
  • 10
    Feb
    14
    News Release
    Hybrigenics draws 500,000 euros from Yorkville facility
  • 4
    Feb
    14
    News Release
    Hybrigenics updates market on Phase II clinical trials for inecalcitol in chronic lymphocytic leukemia
  • 27
    Jan
    14
    News Release
    2013 Operating Revenue up 22% from previous year
  • 20
    Jan
    14
    News Release
    Hybrigenics and Servier achieve first milestone in research partnership
  • 8
    Jan
    14
    News Release
    Hybrigenics draws 550,000 euros from Yorkville facility
  • 8
    Jul
    13
    Equity Research
    Hybrigenics - Arrowhead Research